Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $9.00.

Several equities analysts have commented on PYXS shares. Royal Bank Of Canada reiterated an "outperform" rating and issued a $8.00 price objective on shares of Pyxis Oncology in a report on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Pyxis Oncology in a research report on Monday, May 19th.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently bought and sold shares of the company. ProShare Advisors LLC bought a new stake in Pyxis Oncology during the fourth quarter worth about $26,000. Caption Management LLC bought a new stake in Pyxis Oncology during the fourth quarter worth about $35,000. Ameriprise Financial Inc. acquired a new position in Pyxis Oncology during the fourth quarter worth about $35,000. Kingstone Capital Partners Texas LLC acquired a new position in Pyxis Oncology during the second quarter worth about $37,000. Finally, Commonwealth Equity Services LLC raised its stake in Pyxis Oncology by 61.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors own 39.09% of the company's stock.

Pyxis Oncology Stock Up 2.6%

Pyxis Oncology stock traded up $0.03 during midday trading on Friday, hitting $1.19. 375,922 shares of the stock were exchanged, compared to its average volume of 726,651. The company has a fifty day simple moving average of $1.19 and a two-hundred day simple moving average of $1.23. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.39. The stock has a market capitalization of $73.72 million, a PE ratio of -0.75 and a beta of 1.13.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06). As a group, equities research analysts anticipate that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.